Overall, HDAC2 inhibition disrupts PD-L1 nuclear translocation, potentially enhancing the therapeutic efficacy of immune checkpoint inhibitors and boosting antitumor immune responses for BC [19]. The gene discussed is CD274; the disease is breast cancer.